Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
Quintarelli C, Guercio M, Manni S, Boffa I, Sinibaldi M, Di Cecca S, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Ciccone R, Orfao A, Martin-Martin L, Gutierrez-Herrero S, Herrero-Garcia M, Cazzaniga G, Nunes V, Songia S, Marcatili P, Marin FI, Ruella M, Bertaina V, Vinti L, Del Bufalo F, Algeri M, Merli P, De Angelis B, Locatelli F.
Quintarelli C, et al.
J Immunother Cancer. 2021 Jun;9(6):e001514. doi: 10.1136/jitc-2020-001514.
J Immunother Cancer. 2021.
PMID: 34135100
Free PMC article.
Chimeric antigen receptor T-cells (CAR T-cells) for the treatment of relapsing/refractory B-cell precursor acute lymphoblastic leukemia have led to exciting clinical results. ...DPs were deeply characterized by flow cytometry and molecular biology for Ig-rearrangements, sh …
Chimeric antigen receptor T-cells (CAR T-cells) for the treatment of relapsing/refractory B-cell precursor acute lymphoblastic leukem …